From SEC EDGAR

Eva Live Launches EvaXCrypto, an AI-Powered Cryptocurrency Trading Software Platform

EvaXCrypto is a software tool that combines AI-powered market analytics and user-configured automated trading strategies with live trade execution…

ALIGN TECHNOLOGY INC

ALIGN TECHNOLOGY ANNOUNCES $270 MILLION ACCELERATED STOCK REPURCHASE AGREEMENT

Cannae Holdings, Inc. Announces Reduction in the Size of its Board of Directors to Ten Members

~ Woodrow Tyler and Mark Linehan will not Stand for Re-election

Ziff Davis Reports Third Quarter 2026 Financial Results

AVAT Reports Preliminary Third Quarter 2026 Financial Results and Treasury Metrics

Retired FalconX collateralized loan in full; holds 13.31 million AVAX as Avalanche gains momentum with NYSE, Goldman Sachs, and the UAE

Perma-Fix Reports Third Quarter 2026 Results, with Sequential Growth of 39% in Revenue and 25% in Treatment Backlog from Second Quarter 2026

Treatment backlog of $19.6 million, up approximately 65% from year-end 2025

UPS Appoints Shannon Eisenhardt to Board of Directors

Victory Capital Holdings, Inc.

Victory Capital Reports Strong Third Quarter 2026 Results, Highlighted by Record Gross Sales and Net Flows

GENCO SHIPPING & TRADING LIMITED ANNOUNCES

Q3 2026 FINANCIAL RESULTS

Nature's Sunshine Reports Third Quarter 2026 Results

LeMaitre Q3 2026 Financial Results

Excelerate Energy, Inc.

Excelerate Energy Reports Strong Third Quarter 2026 Results

Outset Medical Reports Third Quarter 2026 Results

Crane NXT, Co.

Crane NXT Reports Third Quarter 2026 Results

SiTime Reports Third Quarter 2026 Financial Results

Q3 Net Revenue Increased 257% to $298.7 Million

Figma Announces Third Quarter 2026 Financial Results

Q3 revenue grew 43% year-over-year to $391.4 million, $16.4 million above the high-end of prior guidance.

STABILIS SOLUTIONS ANNOUNCES THIRD QUARTER 2026 RESULTS

DELUXE CORP

Contact:

Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals

Oral, highly selective and potent VAV1 molecular glue degrader designed to deliver a differentiated clinical profile across a broad range of…

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues